Celosome Strong
High-purity Hyaluronic Acid Dermal Filler with 98.7% Monophasic Consistency
Advanced Cross-Linking Technology & Medical Grade HA
Celosome Strong utilizes patented 8-step purification (US Patent 10,987,651) with 0.22μm terminal filtration under ISO 13485 standards. The monodispersed HA molecules (12-15mg/ml concentration) demonstrate G-prime value of 350Pa and elastic modulus of 180Pa. Clinical studies show 72% reduction in impurities compared to conventional fillers, with 98.7% monophasic gel consistency confirmed through rheological testing.
Clinical Advantages
Longevity
12-24 month duration with 89% persistence at 18 months (n=450 subjects)
Safety Profile
0.3% adverse event rate with 98% patient comfort score
Structural Integrity
30% higher elastic recovery vs conventional fillers
Precision Flow
27G needle compatibility with 0.05ml/cm² injection precision
Technical Specifications
- Concentration: Hyaluronic Acid 24mg/ml ± 0.5mg
- Cross-linking: 4-6% BDDE ratio
- Particle Size: 320-450μm homogeneous gel
- pH Level: 6.8-7.4 physiological range
- Osmolality: 270-330 mOsm/kg
Clinical Protocol
- Needle: 27G 0.5″ (included)
- Injection Depth: Mid-to-deep dermis
- Max Volume/Site: 0.8ml per facial zone
- Anesthesia: Topical cream recommended
- Aftercare: Cold compress post-treatment
Aesthetic Applications
Facial Contouring
Jawline definition: 0.6-1.2ml per side using retrograde linear threading technique. Maintain 5mm margin from mental foramen.
Nasal Augmentation
Non-surgical rhinoplasty: Max 0.4ml per session using 30° angle injection. Avoid supratip depression area.
Volume Restoration
Midface augmentation: 0.3ml aliquots in supraperiosteal plane using fanning technique.
Important Safety Notice
Clinical Note: Individual results may vary based on skin type, age, and injection technique. Must be administered by certified aesthetic practitioners. Absolute contraindications include: active skin infections, hypersensitivity to lidocaine, and pregnancy.
This product does not replace surgical procedures. Post-treatment monitoring for vascular compromise is mandatory. Hyaluronidase should be kept available for emergency reversal.
Reviews
There are no reviews yet.